AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7986853 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT group (45% caloric intake from LCT 20% emulsion)
Number of subjects: 21
Study 7986853 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT group (45% caloric intake from physical mixture of LCT and MCT at 20% concentration)
Number of subjects: 21
Study 7986853 — intervention group
Group type: COMPARATOR
Intervention: Control group (without lipids, all caloric intake from hypertonic glucose solution)
Number of subjects: 21
Study 7986853 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lipid emulsions (LCT and MCT)
Number of subjects: 21
Study 3142775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin (10 mg twice daily for 4 weeks)
Number of subjects: 18
Study 31150711 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules (DMR)
Number of subjects: 273
Study 31150711 — intervention group
Group type: COMPARATOR
Intervention: Topical ivermectin 1% cream and placebo
Number of subjects: 273
Study 29587698 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN)
Number of subjects: 250
Study 29587698 — intervention group
Group type: COMPARATOR
Intervention: Conventional Care Management (Control)
Number of subjects: 250
Study 27999853 — intervention group
Group type: COMPARATOR
Intervention: Home visit
Number of subjects: 208
Study 27999853 — intervention group
Group type: COMPARATOR
Intervention: Telephone consultation
Number of subjects: 208
Study 27999853 — intervention group
Group type: EXPERIMENTAL
Intervention: Control
Number of subjects: 208
Study 26210844 — intervention group
Group type: EXPERIMENTAL
Intervention: RITA-T (Rapid Interactive Screening Test for Autism in Toddlers)
Number of subjects: 61
Study 26210844 — intervention group
Group type: EXPERIMENTAL
Intervention: RITA-T
Number of subjects: 61
Study 23117026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 62
Study 23117026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 21359174 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller weight at birth
Number of subjects: 140
Study 21359174 — intervention group
Group type: EXPERIMENTAL
Intervention: Low birth weight for placental weight
Number of subjects: 140
Study 18927312 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (30, 120, or 180 mg subcutaneously every 4 weeks; 60 or 180 mg every 12 weeks)
Number of subjects: 255
Study 18927312 — intervention group
Group type: COMPARATOR
Intervention: IV Bisphosphonate (open-label)
Number of subjects: 255
Study 18927312 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 255
Study 18927312 — intervention group
Group type: COMPARATOR
Intervention: IV Bisphosphonate
Number of subjects: 255
Study 18927312 — intervention group
Group type: COMPARATOR
Intervention: Denosumab and IV Bisphosphonate
Number of subjects: 255
Study 16330868 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemicraniectomy and hypothermia (HH)
Number of subjects: 25
Study 16330868 — intervention group
Group type: COMPARATOR
Intervention: Hemicraniectomy alone (HA)
Number of subjects: 25
Study 12859265 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% olopatadine hydrochloride
Number of subjects: 40
Study 12859265 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ketorolac tromethamine
Number of subjects: 40
Study 12859265 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for olopatadine)
Number of subjects: 40
Study 12859265 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for ketorolac)
Number of subjects: 40
Study 11055129 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-stage sinus inlay bone grafts
Number of subjects: 40
Study 11055129 — intervention group
Group type: COMPARATOR
Intervention: 2-stage sinus inlay bone grafts
Number of subjects: 40
Study 11055129 — intervention group
Group type: COMPARATOR
Intervention: Non-grafted areas
Number of subjects: 40
Study 8638357 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg three times daily
Number of subjects: 372
Study 8638357 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 125 mg twice daily
Number of subjects: 372
Study 8638357 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg once daily
Number of subjects: 372
Study 8638357 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg twice daily
Number of subjects: 372
Study 8638357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 8638357 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (all doses)
Number of subjects: 372
Study 1602504 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 3.5 g ampicillin plus 1 g probenecid
Number of subjects: 202
Study 1602504 — intervention group
Group type: COMPARATOR
Intervention: 500 mg ampicillin orally four times a day for 10 days
Number of subjects: 202
Study 6442211 — intervention group
Group type: EXPERIMENTAL
Intervention: Home treatment
Number of subjects: 155
Study 6442211 — intervention group
Group type: COMPARATOR
Intervention: Hospital treatment
Number of subjects: 155
Study 6442211 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 155
Study 29720327 — intervention group
Group type: EXPERIMENTAL
Intervention: occlusal splint (MOS)
Number of subjects: 60
Study 29720327 — intervention group
Group type: EXPERIMENTAL
Intervention: clear aligners (CAT)
Number of subjects: 60
Study 29720327 — intervention group
Group type: COMPARATOR
Intervention: placebo splint (PMS)
Number of subjects: 60
Study 26656481 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-poverty neighborhoods intervention
Number of subjects: 1550
Study 24799159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine group (n = 31) received intravenous ketamine 1 mg/kg before incision, followed by 2 μg/kg/minute infusion for 72 hours plus sufentanil patient‐controlled intravenous analgesia after thoracotomy.
Number of subjects: 78
Study 24799159 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 47) received intravenous 0.9% normal saline and infusion plus sufentanil patient‐controlled intravenous analgesia.
Number of subjects: 78
Study 22559905 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention describing goals-of-care options
Number of subjects: 101
Study 22559905 — intervention group
Group type: COMPARATOR
Intervention: Verbal narrative (control) describing goals-of-care options
Number of subjects: 101
Study 19232412 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-CRP
Number of subjects: 82
Study 19232412 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 82
Study 19080323 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 19080323 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus Endostar
Number of subjects: 0
Study 15767771 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% ketoconazole gel
Number of subjects: 45
Study 15767771 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% ketoconazole cream
Number of subjects: 45
Study 15767771 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 2% ketoconazole and 0.05% desonide
Number of subjects: 45
Study 15767771 — intervention group
Group type: COMPARATOR
Intervention: 0.05% desonide gel
Number of subjects: 45
Study 15767771 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (unmedicated gel)
Number of subjects: 45
Study 14666761 — intervention group
Group type: EXPERIMENTAL
Intervention: Yishen Jianpi Yangxue Tongli Therapy (YJYTT)
Number of subjects: 107
Study 14666761 — intervention group
Group type: COMPARATOR
Intervention: Clomiphen
Number of subjects: 107
Study 11022059 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention (carotid endarterectomy)
Number of subjects: 1648
Study 11022059 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 1648
Study 9029411 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF levels of dopamine, noradrenaline, 3,4‐dihydroxyphenylacetic acid, homovanillic acid, 3‐methoxy‐4‐hydroxyphenylglycol and 5‐hydroxyindole acetic acid, determined by high‐performance liquid chromatography
Number of subjects: 26
Study 9029411 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF levels of serotonin metabolites
Number of subjects: 26
Study 1377457 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES (molecular weight average: 450,000)
Number of subjects: 40
Study 1377457 — intervention group
Group type: COMPARATOR
Intervention: 5% human albumin
Number of subjects: 40
Study 6316420 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 ng/kg/min PGI2 X Na for 72 hrs
Number of subjects: 6
Study 6316420 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 ng/kg/min PGI2 X Na infusion abruptly terminated
Number of subjects: 6
Study 6316420 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 ng/kg/min PGI2 X Na infusion tapered off over 12 hrs
Number of subjects: 6
Study 6316420 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 ng/kg/min PGI2
Number of subjects: 6
Study 6316420 — intervention group
Group type: COMPARATOR
Intervention: 0 (buffer)
Number of subjects: 6
Study 30921762 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the M1
Number of subjects: 20
Study 30921762 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the DLPFC
Number of subjects: 20
Study 30921762 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20
Study 29926316 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component exercise training for 12 weeks
Number of subjects: 110
Study 29926316 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive functioning
Number of subjects: 110
Study 26476404 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval exercise (HIIE) 10×60s (85‐90%PMax)/75s (50%PMax)
Number of subjects: 22
Study 26476404 — intervention group
Group type: COMPARATOR
Intervention: Moderate intensity interval exercise (MIIE) 10×60s (70‐75%PMax)/60s (50%PMax)
Number of subjects: 22
Study 24486675 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel microabrasion (GI) using 37% phosphoric acid and pumice
Number of subjects: 70
Study 24486675 — intervention group
Group type: EXPERIMENTAL
Intervention: Microabrasion associated with at-home bleaching (GII) using 10% carbamide peroxide
Number of subjects: 70
Study 22913289 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified FACIT-F scale
Number of subjects: 2107
Study 22913289 — intervention group
Group type: EXPERIMENTAL
Intervention: Original FACIT-F scale
Number of subjects: 2107
Study 20565455 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA fluticasone/salmeterol (FP/SM) 250/25 microg via pMDI
Number of subjects: 2
Study 20565455 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA fluticasone/salmeterol (FP/SM) 250/25 microg via spacer (4 puffs)
Number of subjects: 2
Study 20565455 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA fluticasone/salmeterol (FP/SM) 250/25 microg via spacer (8 puffs)
Number of subjects: 2
Study 20565455 — intervention group
Group type: COMPARATOR
Intervention: Reference product Seretide (GlaxoSmithKline, UK)
Number of subjects: 2
Study 17070671 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive remediation (12-month intervention)
Number of subjects: 42
Study 17070671 — intervention group
Group type: COMPARATOR
Intervention: Computer-skills training (control condition)
Number of subjects: 42
Study 15863468 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (1x10(9)Lactobacillus fermentum VRI‐033 PCC; Probiomics), twice daily for 8 weeks
Number of subjects: 56
Study 15863468 — intervention group
Group type: COMPARATOR
Intervention: Placebo, equivalent volume, twice daily for 8 weeks
Number of subjects: 56
Study 15863468 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic
Number of subjects: 56
Study 15863468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 12546089 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix allograft (ADMA)
Number of subjects: 7
Study 12546089 — intervention group
Group type: COMPARATOR
Intervention: Subepithelial connective tissue grafts (CTG)
Number of subjects: 7
Study 10802909 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient supplements (B vitamins and minerals) administered semi-blinded for the first year, double-blinded in crossover rotations during the second year, and open-label in the ensuing years.
Number of subjects: 20
Study 10802909 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient supplements continued for at least 2 additional years after the 1-year double-blind phase.
Number of subjects: 20
Study 10802909 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of nutrient supplements after the 1-year double-blind phase.
Number of subjects: 20
Study 8816620 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone agonist administered intranasally from day 1 of menstrual cycle
Number of subjects: 86
Study 8816620 — intervention group
Group type: COMPARATOR
Intervention: Gonadotropin-releasing hormone agonist administered intranasally from day 21 of menstrual cycle
Number of subjects: 86
Study 1574019 — intervention group
Group type: EXPERIMENTAL
Intervention: PVRV (Purified Vero Rabies Vaccine)
Number of subjects: 90
Study 1574019 — intervention group
Group type: EXPERIMENTAL
Intervention: HDCV (Human Diploid Cell Vaccine)
Number of subjects: 90
Study 1574019 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PS)
Number of subjects: 90
Study 3998911 — intervention group
Group type: EXPERIMENTAL
Intervention: Holding room treatment
Number of subjects: 103
Study 3998911 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization
Number of subjects: 103
Study 3998911 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study 30801952 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercise program (LSEP)
Number of subjects: 31
Study 30801952 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 31
Study 30879451 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative Rotation Control Method (IRCM)
Number of subjects: 42
Study 30879451 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 42
Study 26267817 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated triple influenza vaccine (TIV)
Number of subjects: 0
Study 26267817 — intervention group
Group type: COMPARATOR
Intervention: Monovalent anti-A(H1N1)pdm09 vaccine
Number of subjects: 0
Study 24502372 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 243
Study 24502372 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed messages
Number of subjects: 243
Study 24502372 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 243
Study 22472896 — intervention group
Group type: EXPERIMENTAL
Intervention: Mena expression in malignant tumors (salivary duct carcinomas, carcinomas in pleomorphic adenoma, acinic cell carcinomas, squamous cell carcinomas, high-grade mucoepidermoid carcinomas)
Number of subjects: 65
Study 22472896 — intervention group
Group type: COMPARATOR
Intervention: Mena expression in benign tumors (pleomorphic adenomas, Warthin's tumors)
Number of subjects: 65
Study 22472896 — intervention group
Group type: COMPARATOR
Intervention: Mena expression in normal salivary glands
Number of subjects: 65
Study 22472896 — intervention group
Group type: COMPARATOR
Intervention: Mena expression in lymphomas and low-grade mucoepidermoid carcinomas
Number of subjects: 65
Study 22472896 — intervention group
Group type: EXPERIMENTAL
Intervention: Mena expression in endothelial cells of peritumoral vessels
Number of subjects: 65
Study 21140088 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 50
Study 21140088 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia with sedation
Number of subjects: 50
Study 17434401 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg raltegravir
Number of subjects: 179
Study 17434401 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg raltegravir
Number of subjects: 179
Study 17434401 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg raltegravir
Number of subjects: 179
Study 17434401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 16130850 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course of prophylactic antibiotics (administered for < 24 hours)
Number of subjects: 156
Study 12160501 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrathin EGD
Number of subjects: 72
Study 12160501 — intervention group
Group type: COMPARATOR
Intervention: Conventional EGD
Number of subjects: 72
Study 10853565 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% plain prilocaine
Number of subjects: 150
Study 10853565 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 150
Study 10853565 — intervention group
Group type: COMPARATOR
Intervention: 2% mepivacaine with 1:20,000 levonordefrin
Number of subjects: 150
Study 7575822 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerin enema (1 mL of glycerin mixed with 1 mL of warmed normal saline) within 30 minutes after birth and repeated at 12 hours of age
Number of subjects: 265
Study 7575822 — intervention group
Group type: COMPARATOR
Intervention: No glycerin enema throughout their hospital stay
Number of subjects: 265
Study 2276191 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate (with sodium)
Number of subjects: 30
Study 2276191 — intervention group
Group type: COMPARATOR
Intervention: Iohexol (without sodium)
Number of subjects: 30
Study 31563272 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged intermittent theta burst stimulation (piTBS) monotherapy
Number of subjects: 105
Study 31563272 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) monotherapy
Number of subjects: 105
Study 31563272 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 105
Study 31172174 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% Leu supplementation
Number of subjects: 240
Study 31172174 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45% Leu supplementation
Number of subjects: 240
Study 31172174 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.05% Leu supplementation
Number of subjects: 240
Study 31172174 — intervention group
Group type: COMPARATOR
Intervention: Positive Control (PC) diet
Number of subjects: 240
Study 31172174 — intervention group
Group type: COMPARATOR
Intervention: Negative Control (NC) diet
Number of subjects: 240
Study 28236956 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as usual plus a financial reward for each depot of medication received (€30 per month if fully compliant)
Number of subjects: 169
Study 28236956 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 169
Study 26582851 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg p.o. before surgery and 75 mg twice daily in hospital and for 7 days after discharge
Number of subjects: 184
Study 26582851 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 184
Study 26582851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 23490761 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving bibliotherapy intervention
Number of subjects: 124
Study 21692760 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex dosed at 2 mg.kg(‐1) based on ideal body weight + 40%
Number of subjects: 100
Study 21692760 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex dosed at 2 mg.kg(‐1) based on ideal body weight
Number of subjects: 100
Study 21692760 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex dosed at 2 mg.kg(‐1) based on ideal body weight + 20%
Number of subjects: 100
Study 21692760 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex dosed at 2 mg.kg(‐1) based on real body weight
Number of subjects: 100
Study 19209073 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (3.2 km of interval running, 1:1 work:rest ratio, 3 times a week for 8 weeks at 90% of maximal heart rate)
Number of subjects: 36
Study 19209073 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 36
Study 16899730 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal amnesia
Number of subjects: 0
Study 16899730 — intervention group
Group type: COMPARATOR
Intervention: Short lags
Number of subjects: 0
Study 15187195 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 91
Study 15187195 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxacalcitol
Number of subjects: 91
Study 15187195 — intervention group
Group type: COMPARATOR
Intervention: Calcitriol and Maxacalcitol
Number of subjects: 91
Study 11693875 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate plus sulfadoxine-pyrimethamine
Number of subjects: 105
Study 11693875 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine alone
Number of subjects: 105
Study 9863092 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangke Injection (RSF)
Number of subjects: 76
Study 9863092 — intervention group
Group type: COMPARATOR
Intervention: Glucose-insulin-potassium chloride (GIK)
Number of subjects: 76
Study 7887117 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse Sequence Induction (ISI) with atracurium 0.6 mg.kg‐1 followed by thiopental 5 mg.kg‐1
Number of subjects: 60
Study 7887117 — intervention group
Group type: COMPARATOR
Intervention: Rapid Sequence Induction (RSI) with succinylcholine (SUX) precurarized with atracurium 0.06 mg.kg‐1 followed by thiopental 5 mg.kg‐1 and succinylcholine 1.5 mg.kg‐1
Number of subjects: 60
Study 7887117 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 2905148 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam 15 mg (active control)
Number of subjects: 12
Study 2905148 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 12
Study 2905148 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 12
Study 2905148 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 12
Study 2905148 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 12